OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 20:54 UTC. Every row links to its source record.

NF2 NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor

ENSG00000186575 · protein coding · Open Targets profile

Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex. {ECO:0000269|PubMed:20159598, ECO:0000269|PubMed:20178741, ECO:0000269|PubMed:21167305}.

In 8 of 15 cancers, the evidence for NF2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751NF2-related schwannomatosisNF2-related schwannomatosisNF2-related schwannomatosis: somatic 0.58NF2-related schwannomatosis: germline 0.93schwannomatosisschwannomatosisschwannomatosis: somatic 0.68schwannomatosis: germline 0.80SMARCB1-related schwannomatosisSMARCB1-related schwannomatosisSMARCB1-related schwannomatosis: somatic 0.68SMARCB1-related schwannomatosis: germline 0.80familial meningiomafamilial meningiomafamilial meningioma: germline 0.83acoustic neuromaacoustic neuromaacoustic neuroma: germline 0.60pleural mesotheliomapleural mesotheliomapleural mesothelioma: somatic 0.81hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.93neurofibromatosisneurofibromatosismeningiomameningiomameningioma: somatic 0.60meningioma: germline 0.27schwannomaschwannomaschwannoma: somatic 0.61renal cell carcinomarenal cell carcinomarenal cell carcinoma: somatic 0.55malignant mesotheliomamalignant mesotheliomamalignant mesothelioma: somatic 0.61Meningothelial MeningiomaMeningothelial MeningiomaMeningothelial Meningioma: somatic 0.61Chordoid MeningiomaChordoid MeningiomaChordoid Meningioma: somatic 0.61Fibrous MeningiomaFibrous MeningiomaFibrous Meningioma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Pocket
Antibody
GO CC high conf, UniProt loc med conf, Human Protein Atlas loc
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.09553699940443039 (upper bound 0.1723800003528595). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of NF2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of NF2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.